Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsAddiction psychiatry — substance-induced mood and anxiety disorders

Psych MEQs / SAQs · Addiction psychiatry — substance-induced mood and anxiety disorders

Substance-induced mood and anxiety — timing, alcohol and dual care (MEQ)

FRANZCP-style MEQ on substance-induced depression: DSM timing rules, assessment, watchful waiting vs SSRI, naltrexone, Brown/Schuckit and Nunes/Pettinati evidence.

20 marks20 min2 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 46-year-old man with 10 years of heavy daily alcohol use is admitted for detox. For 4 weeks while drinking he has had anhedonia, early morning waking, guilt and passive suicidal ideation. He has no prior depressive episodes during two previous 3-month sober periods. CIWA is moderate; he is medically stable after thiamine and a reducing diazepam protocol. (i) Define substance/medication-induced depressive disorder and state key discriminators from independent MDD and delirium. (ii) Outline assessment priorities including suicide risk and investigations. (iii) Give a definitive dual management plan including when you would watch-and-wait versus start a named antidepressant with dose, plus one AUD medicine with dose. (iv) Counsel on prognosis using named evidence. (20 marks)

Model answer

Reveal model answerShowHide

(i) Definition and discriminators. Substance/medication-induced depressive disorder is a prominent depressed mood and/or anhedonia developing during or soon after intoxication, withdrawal or a culprit medication capable of producing the symptoms, not better explained by independent depression, not exclusively during delirium, and causing distress/impairment. Discriminators: delirium shows fluctuating attention and medical instability; independent MDD is favoured by offline episodes, family history of mood disorder, and persistence substantially beyond the expected abstinence window. Here, symptoms track heavy drinking with prior sober periods free of depression — favours induced, still provisional.[1]

(ii) Assessment and investigations. Rebuild timeline (10 years heavy use, 4 weeks depressive syndrome while drinking, prior sober periods without MDD), collateral, MSE, explicit suicide risk (ideation, intent, plan, means, protective factors), capacity/legal status under local principles (no invented section numbers), and AUD criteria. Investigations: observations/CIWA ongoing; FBC, U&E, LFT, glucose, TFT as indicated, pregnancy test if applicable; UDS if other substances suspected; ECG before some antidepressants. Thiamine already given — continue Wernicke prevention per protocol.[1][2]

(iii) Dual management. Medical detox and suicide safety first. Disease-modifying core: abstinence support with MI/CBT and AUD pharmacotherapy — example naltrexone 50 mg oral daily if opioid-free (LFT counselling; opioid analgesia blocked). For depression: watchful waiting ~2–4 weeks of abstinence is reasonable if risk is contained and history strongly suggests pure induced depression (Brown/Schuckit early remission curve). Start antidepressant earlier if severity/suicide risk escalates or independent features emerge — example sertraline 50 mg oral daily, titrate as tolerated, review risk and side-effects early. Pettinati-style dual thinking: treat both axes (sertraline + naltrexone in selected patients). Integrated concurrent care, not sequential exclusion; written crisis plan; early follow-up.[2][3][4][5]

(iv) Prognosis counselling. Many alcohol-related depressive symptoms improve substantially with sustained abstinence (Brown & Schuckit). Independent MDD remains possible and would need full mood care. Dual prognosis worsens with ongoing drinking; treating both axes improves outcomes framing. Name Nunes/Levin modest antidepressant benefit when depression is carefully diagnosed; name Pettinati combination signal for drinking outcomes. Reassess diagnosis at 2–4 weeks and after sustained abstinence.[2][3][4]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]Schuckit MA, Tipp JE, Bergman M, et al. Comparison of induced and independent major depressive disorders in 2,945 alcoholics Am J Psychiatry, 1997.PMID 9210745
  2. [2]Brown SA, Schuckit MA Changes in depression among abstinent alcoholics J Stud Alcohol, 1988.PMID 3216643
  3. [3]Nunes EV, Levin FR Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis JAMA, 2004.PMID 15100209
  4. [4]Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence Am J Psychiatry, 2010.PMID 20231324
  5. [5]Drake RE, Mercer-McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders Schizophr Bull, 1998.PMID 9853791
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousStructure and interpret a complete Mental State Examination (MEQ)Professional skills — mental state examinationNextSubstance-induced psychosis — timeline, conversion and dual care (MEQ)General adult psychiatry — substance/medication-induced psychosis